Publications by authors named "S Colloca"
Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous prime/boost administration of two multivalent viral vector products: GAd-209 and MVA-209. These consist of a mix of four Adeno (Great Ape Adenovirus; GAd) and four Modified Vaccinia Ankara (MVA) vectors respectively, each containing a different transgene encoding a synthetic polypeptide composed of antigenic peptide fragments joined one after the other.
View Article and Find Full Text PDFSARS-CoV-2 continues to pose a global threat, and current vaccines, while effective against severe illness, fall short in preventing transmission. To address this challenge, there's a need for vaccines that induce mucosal immunity and can rapidly control the virus. In this study, we demonstrate that a single immunization with a novel gorilla adenovirus-based vaccine (GRAd) carrying the pre-fusion stabilized Spike protein (S-2P) in non-human primates provided protective immunity for over one year against the BA.
View Article and Find Full Text PDFArticle Synopsis
- The GRAd-COV2 vaccine, developed from a gorilla adenovirus, aims to enhance COVID-19 immunity with a focus on a stable spike protein.
- In a phase 2 trial with 917 participants, the vaccine demonstrated good safety and strong immune responses, especially after a second dose.
- The vaccine effectively generated a robust T cell response, particularly CD8 T cells, suggesting its potential for future genetic vaccine development in combating variants of concern.
Gene therapy of Usher syndrome type 1B (USH1B) due to mutations in the large () gene is limited by the packaging capacity of adeno-associated viral (AAV) vectors. To overcome this, we have previously developed dual AAV8 vectors which encode human (dual AAV8.).
View Article and Find Full Text PDFArticle Synopsis
- Development of new vaccines for SARS-CoV-2 aims to improve availability in low-income areas, despite existing effective vaccines.
- A study tracked immune responses in young and old volunteers after receiving the GRAd-COV2 vaccine, showing strong antibody and T-cell responses that were maintained for 3 months but declined by 6 months.
- GRAd-COV2 demonstrated good safety and immune response, making it a promising candidate for further clinical development as part of the COVID-19 vaccination strategy.